The acetylcholinesterase inhibitors (Donepezil, Galantamine and Rivastigmine) and the glutamatergic NMDA receptor antagonist (i.e. Memantine) that have been approved by FDA for the treatment provide symptomatic relief for only a fraction of AD patients33,56. This evidence concerns the gene ACHE and Alzheimer disease.